Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
11 hedge funds and large institutions have $1.77M invested in Altamira Therapeutics Ltd in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
13% less call options, than puts
Call options by funds: $250K | Put options by funds: $289K
23% less capital invested
Capital invested by funds: $2.31M → $1.77M (-$538K)
27% less funds holding
Funds holding: 15 → 11 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$65.9K |
| 2 |
Squarepoint
New York
|
+$34.3K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$13.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.49K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$196K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$180K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$156K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$69K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.9K |
CYTO Hedge Fund Activity: Q2 2021 in Review
11 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2021, worth a combined $1.77M — down 23% from $2.31M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CYTO and 4 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Group One Trading, adding an estimated $65.9K. The largest seller was Ikarian Capital, cutting an estimated $196K.
- 11 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2021, down from 15 in Q1 2021.
- Funds reported $1.77M of Altamira Therapeutics Ltd stock for Q2 2021, down 23% quarter-over-quarter.
- 4 funds opened new Altamira Therapeutics Ltd positions in Q2 2021 and 8 closed out, a net change of -4 holders.
- The largest Altamira Therapeutics Ltd buyer in Q2 2021 was Group One Trading, an estimated $65.9K added.
- The largest Altamira Therapeutics Ltd seller in Q2 2021 was Ikarian Capital, an estimated $196K sold.
Based on aggregated 13F filings for Q2 2021.